Abstract
Chronic hepatitis B virus infection (HBV) continues to pose a serious global health threat in many areas of the world, particularly in sub-Saharan Africa, the Western Pacific Region and areas of Eastern Europe. Endemicity is heterogeneous within and across regions owing to variable implementation of childhood and birth-dose vaccination programs, inconsistent screening of blood products, injection drug use, and poor education initiatives. This review aims to provide comprehensive up-to-date estimates of global seroprevalence of chronic HBV across six World Health Organization (WHO) regions, noting patterns of change over time and highlighting potential region-specific barriers to the diagnosis and elimination of HBV.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
